Skip to Main Content
Pharmacology & Chemical Biology Seminar Series
2/17/2022 - 12:00 PM-1:00 PM
“The Opportunities and Challenges of Developing Novel Therapeutics for Parkinson’s Disease”

Warren Hirst, PhD
Senior Director
Biogen

Over the past 20 years there has been considerable progress in the understanding the genetic basis of Parkinson’s disease (PD).  The genetics have complemented human pathology and we now have an increased knowledge of the disease pathophysiology with lysosomal dysfunction, endosomal trafficking, mitochondrial quality control and immune response being the predominant pathways linked to PD.  This has provided us with well validated therapeutic targets, including a-synuclein, LRRK2, GBA and Parkin.  I will present and discuss the opportunities and challenges of developing novel therapeutics to these targets and how we are linking familial and sporadic forms of the disease in preclinical research and in clinical development.

 

Contact
Melanie Hoffner

QR Code for Event